Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: Protease inhibitors and NSAIDs in a meta-analysis

Journal of Gastroenterology

Volumn 49, Issue 3, 2014, Pages 388-399

  Yuhara, Hiroki ^a   Ogawa, Masami ^a   Kawaguchi, Yoshiaki ^a   Igarashi, Muneki ^a   Shimosegawa, Tooru ^b   Mine, Tetsuya ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gabexate mesilate; Nafamostat mesilate; NSAIDs; Post ERCP pancreatitis; Protease inhibitor; Ulinastatin

Indexed keywords

GABEXATE MESILATE; NAFAMSTAT MESILATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE INHIBITOR; ULINASTATIN; GUANIDINE DERIVATIVE; NAFAMSTAT;

CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SCREENING; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; META ANALYSIS (TOPIC); PANCREATITIS; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COMPARATIVE STUDY; META ANALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; GUANIDINES; HUMANS; PANCREATITIS; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897110895     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0834-x     Document Type: Review

References (84)

1. McCune WS, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of Vater: a preliminary report. Ann Surg. 1968;167:752-6.
2. Mazen JM, Yoon EJ, Saadi A, et al. Trends in the utilization of endoscopic retrograde cholangiopancreatography (ERCP) in the United States. Am J Gastroenterol. 2007;102(5):966-75. (Pubitemid 46698233)
3. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004;59:845-64. (Pubitemid 38879313)
4. Rabenstein T, Hahn EG. Post-ERCP pancreatitis: new momentum. Endoscopy. 2002;34:325-9. (Pubitemid 34279524)
5. Dumonceau JM, Andriulli A, Deviere J, European Society of Gastrointestinal Endoscopy. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy. 2010;42:503-15.
6. Prat F, Amaris J, Ducot B. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc. 2002;56:202-8.
7. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion. 1993;54:105-11. (Pubitemid 23160626)
8. Schwartz JJ, Lew RJ, Ahmad NA. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc. 2004;59:179-84. (Pubitemid 38199209)
9. Xu LH, Qian JB, Gu LG. Prevention of postendoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla. J Gastroenterol Hepatol. 2011;26:1139-44.
10. Andriulli A, Leandro G, Federici T. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc. 2007;65:624-32. (Pubitemid 46442832)
11. Bai Y, Gao J, Zou DW, Li ZS. Prophylactic octreotide administration does not prevent postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Pancreas. 2008;37:241-6.
12. Omata F, Deshpande G, Tokuda Y, Takahashi O, Ohde S, Carr-Locke DL, Jacobs JL, Mine T, Fukui T. Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J Gastroenterol. 2010;45(8):885-95.
13. Bai Y, Gao J, Shi X. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology. 2008;8:504-9.
14. Zheng M, Chen Y, Bai J. Meta-analysis of prophylactic allopurinol use in postendoscopic retrograde cholangiopancreatography pancreatitis. Pancreas. 2008;37:247-53.
15. Katsinelos P, Kountouras J, Paroutoglou G. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc. 2005;62:105-11. (Pubitemid 40922448)
16. Rabenstein T, Fischer B, Wiessner V. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc. 2004;59:606-13. (Pubitemid 38609687)
17. Oh HC, Cheon YK, Cho YD, Do JH. Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial. Gastrointest Endosc. 2011;74:556-62.
18. Sherman S, Cheng C-L, Costamagna G. Efficacy of recombinant human interleukin-10 in prevention of postendoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas. 2009;38:267-74.
19. George S, Kulkarni AA, Stevens G. Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci. 2004;49:503-8. (Pubitemid 38453572)
20. Kishida S, Takeyama Y, Ueda T, et al. Clinical effects of ulinastatin on severe acute pancreatitis. Shokakika. 1994;19:424-32.
21. Chen SY, Wang JY. Ulinastatin in the treatment of acute pancreatitis: a multicenter clinical trial. Chin J Dig. 2002;3:70-4. (Pubitemid 34700373)
22. Hara A, Arai J, Matsukawa H, et al. Combination therapy of continuous arterial infusion of nafamostat mesilate and arterial injection of human urinary trypsin inhibitor (ulinastatin) for severe acute pancreatitis. Ther Res. 2002;23:1265-75. (Pubitemid 35239002)
23. Cavallini G, Tittobello A, Frulloni L, The Gabexate in Digestive Endoscopy-Italian Group, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med. 1996;335:919-23. (Pubitemid 26314444)
24. Masci E, Cavallini G, Mariani A, The Gabexate in Digestive Endoscopy-Italian Group II, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol. 2003;98:2182-6. (Pubitemid 37305356)
25. Sugiura Y, Nakajima K, Kawase H, et al. Evaluation of a large dose intravenous administration of ulinastatin. Jpn J Acute Med. 1988;12:1153-6.
26. Ohara H, Goto K, Noguchi Y, et al. The usefulness of ulinastatin for post-ERCP pancreatitis and hyperpancreatoenzymemia-comparative examination between one-shot injection and drip infusion of ulinastatin. Gastroenterology (Tokyo). 1990;12:361-8.
27. Yoo KS, Huh KR, Kim YJ. Nafamostat mesilate for prevention of postendoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial. Pancreas. 2011;40:181-6.
28. Seta T, Noguchi Y. Protease inhibitors for preventing complications associated with ERCP: an updated metaanalysis. Gastrointest Endosc. 2011;73:700-6.
29. Dumonceau JM, Andriulli A, Deviere J, et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy. 2010;42:503.
30. ASGE Standards of Practice Committee, Anderson MA, Fisher L, Jain R. Complications of ERCP. Gastrointest Endosc. 2012;75(3):467-73.
31. http://www.jges.net/index.html.
32. Gross V, Leser HG, Heinisch A, et al. Inflammatory mediators and cytokines - new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology. 1993;40:522-30. (Pubitemid 24006279)
33. Mäkelä A, Kuusi T, Schröder T. Inhibition of serum phospholi-pase- A2 in acute pancreatitis by pharmacologic agents in vitro. Scand J Clin Lab Invest. 1997;57:401-8.
34. Dumonceau JM, Rigaux J, Kahaleh M, Gomez CM, Vandermeeren A, Devière J. Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastrointest Endosc. 2010;71(6):934-9.
35. Zheng M, Chen Y, Yang X, et al. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2007;7:6.
36. Chen S, Shi H, Zou X, Luo H. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp? Pancreas. 2010;39(8):1231-7.
37. Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008;57(9):1262-7.
38. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. (Pubitemid 26120810)
39. Greenland S. Meta-analysis. In: Rothman K, Greenland S, editors. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott Raven; 1998. p. 643-73.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. (Pubitemid 17189972)
41. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-58.
42. Egger M, DaveySmith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629-34.
43. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
44. Cavallini G, Tittobello A, Frulloni L. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med. 1996;335(13):919-23. (Pubitemid 26314444)
45. Andriulli A, Clemente R, Solmi L. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002;56(4):488-95.
46. Yokohata K, Maeyama R, Nagata M, et al. Gastoenterol Endoscopy. 2003;45(Suppl 1):567.
47. Andriulli A, Solmi L, Loperfido S. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol. 2004;2(8):713-8. (Pubitemid 39013432)
48. Xiong GS, Wu SM, Zhang XW. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res. 2006;39(1):85-90 Epub 2005 Dec 15.
49. Manes G, Ardizzone S, Lombardi G, Uomo G, Pieramico O, Porro GB. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc. 2007;65(7):982-7. (Pubitemid 46783824)
50. Yoo YW, Cha SW, Kim A. The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Gut Liver. 2012;6(2):256-61.
51. Tsujino T, Komatsu Y, Isayama H. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3(4):376-83. (Pubitemid 40488346)
52. Gong P, Wang ZY, Tai PJ, et al. Prevention and treatment for post ERCP pancreatitis. J Hepatobiliary Surg. 2004;12:101-3.
53. Song AL, Yin LN, Kou ZM. Preventive effects of ulinastatin on post ERCP hyperamylasemia and acute pancreatitis. J Lanzhou Univ (Med Sci). 2005;31:24-5.
54. Chen XT, Fei ZY, Shen YF, et al. Clinical observation on ulinastatin for the prevention of post-ERCP pancreatitis. Shandong Med J. 2005;45:44-5.
55. Yoo JW, Ryu JK, Lee SH. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebocontrolled trial. Pancreas. 2008;37(4):366-70.
56. Choi CW, Kang DH, Kim GH. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc. 2009;69(4):e11-8.
57. Yamashita Y, Ito K, Noda H, et al. Gastoenterol Endosc. 2010;52(Suppl 1):1048.
58. Park KT, Kang DH, Choi CW. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? Pancreas. 2011;40(8):1215-9.
59. Yoo KS, Huh KR, Kim YJ. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial. Pancreas. 2011;40(2):181-6.
60. Ohuchida J, Ashiyoshi M, Chijiiwa K. Gastoenterol Endosc. 2011;53(Suppl 2):2445.
61. Murray B, Carter R, Imrie C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003;124(7):1786-91. (Pubitemid 36666775)
62. Sotoudehmanesh R, Khatibian M, Kolahdoozan S. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007;102(5):978-83.
63. MontañoLoza A, RodríguezLomelí X, GarcíaCorrea JE. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Rev Esp Enferm Dig. 2007;99(6):330-6.
64. Khoshbaten M, Khorram H, Madad L. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008;23(7 Pt 2):e11-6. (Pubitemid 352019420)
65. Cheon YK, Cho KB, Watkins JL. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc. 2007;66(6):1126-32. (Pubitemid 350179792)
66. Senol A, Saritas U, Demirkan H. Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol. 2009;15(32):3999-4004.
67. Bhatia V, Ahuja V, Acharya SK. A randomized controlled trial of valdecoxib and glyceryl trinitrate for the prevention of post-ERCP pancreatitis. J Clin Gastroenterol. 2011;45(2):170-6.
68. Elmunzer BJ, Scheiman JM, Lehman GA, U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012;366(15):1414-22.
69. Otsuka T, Kawazoe S, Nakashita S. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol. 2012;47(8):912-7.
70. Fujishiro H, Adachi K, Imaoka T. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol. 2006;21(6):1065-9. (Pubitemid 43823296)
71. Ueki T, Otani K, Kawamoto K, Shimizu A. Comparison between ulinastatin and gabexate mesylate for the prevention of pos-tendoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. J Gastroenterol. 2007;42(2):161-7. (Pubitemid 46404221)
72. Testoni PA. Pharmacological prevention of post-ERCP pancreatitis: the facts and the fiction. JOP. 2004;5:171-8. (Pubitemid 41573864)
73. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661:342-5. (Pubitemid 12233442)
74. Keck T. Site-specific therapeutic effects of protease inhibitors: effect of route of administration in experimental pancreatitis. Pancreatology. 2001;1:656-61. (Pubitemid 33674963)
75. Iwaki M, Ino Y, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41:155-62. (Pubitemid 16078701)
76. Messmann H, Vogt W, Holstege A, et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut. 1997;40:80-5. (Pubitemid 27079755)
77. Karne S, Gorelick FS. Etiopathogenesis of acute pancreatitis. Surg Clin N Am. 1999;79:699-710. (Pubitemid 29383588)
78. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol. 2000;190:117-25. (Pubitemid 30082483)
79. Rabenstein T, Hahn EG. Post-ERCP pancreatitis: new momentum. Endoscopy. 2002;34(4):325-9. (Pubitemid 34279524)
80. Gross V, Leser HG, Heinisch A, Schölmerich J. Inflammatory mediators and cytokines: new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology. 1993;40:522-30. (Pubitemid 24006279)
81. Reddy SC, Draganov PV. ERCP wire systems: the long and the short of it. World J Gastroenterol. 2009;15(1):55-60.
82. Lee TH, Park do H, Park JY, Kim EO, Lee YS, Park JH, Lee SH, Chung IK, Kim HS, Park SH, Kim SJ. Can wire-guided cannulation prevent post-ERCP pancreatitis? A prospective randomized trial. Gastrointest Endosc 2009;69(3 Pt 1):444-9.
83. Ito K, Fujita N, Noda Y, Kobayashi G, Obana T, Horaguchi J, Takasawa O, Koshita S, Kanno Y. Pancreatic guidewire placement for achieving selective biliary cannulation during endoscopic retrograde cholangio-pancreatography. World J Gastroenterol. 2008;14(36):5595-600.
84. Kawaguchi Y, Ogawa M, Omata F, Ito H, Shimosegawa T, Mine T. Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography. World J Gastroenterol. 2012;18(14):1635-41.